Prot #MK‐7684A‐010‐02: A Phase 3, Randomized, Double‐blind, Active‐Comparator‐Controlled Clinical Study of Adjuvant MK‐7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High‐risk Stage II‐IV Melanoma (KEYVIBE‐010

Project: Research project

Project Details

StatusActive
Effective start/end date5/18/235/18/26

Funding

  • Merck Sharp & Dohme LLC (Prot #MK-7684A-010-02)